Filgrastim biosimilar - Biogenomics
Alternative Names: rH-GCSFLatest Information Update: 12 Nov 2021
At a glance
- Originator Biogenomics
- Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor replacements; Granulocyte colony-stimulating factor receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Neutropenia
Most Recent Events
- 28 May 2019 No recent reports of development identified for clinical-Phase-Unknown development in Neutropenia(Chemotherapy-induced) in India (Parenteral, Injection)
- 28 May 2019 No recent reports of development identified for phase-I development in Neutropenia(In volunteers) in India (SC)
- 16 Jan 2014 Research programme: filgrastim biosimilar - Biogenomics is available for licensing in World as of 16 Jan 2014. http://www.biogenomics.co.in